By Mohanad Alfahad( PhD student in the Keele Nanopharmaceutics Research Group, Institute for Science & Technology in Medicine, Keele University)
Nanopharmaceutics Symposium
Successful second annual event at Keele University
The second annual Keele Nanopharmaceutics Symposium took place in the Sustainability Hub at Keele University on 15th July 2016. The symposium, organised by the Keele Nanopharmaceutics group, hosted researchers from other universities and industry from across the UK with common interests in nanodrug formulation. Topics discussed included the use of nanotechnology for the delivery of specific fragments of small interfering RNA, proteins and drugs as well as particulates with multiple uses in both diagnosis and therapy. Guests from across the UK, ranging from PhD students to Professors shared their research findings through a series of invited talks and posters. Speakers included Dr Dimitrios Lamprou from the University of Strathclyde, Professor Afzal Mohammed from Aston University, Dr Yimin Chao from University of East Anglia, Dr Annalisa Tirella from University of Manchester, Dr’ s Clare Hoskins and Neil Telling from Keele University along with others. The event was set up with the aim of providing a forum to promote networking between the scientific community and provide a suitable environment to foster new collaborations.
“
The event was set up with the aim of providing a forum to promote networking between the scientific community and provide a suitable environment to foster new collaborations.
The event was supported by the Royal Society of Chemistry: Chemical Nanosciences and Nanotechnology Network and the British Society of Nanomedicine- two of the key bodies in the UK for such work and their ongoing support has been greatly appreciated by the Keele Nanotherapeutics group. The symposium was well attended and received excellent reviews with firm commitment from key groups for future attendance. The attending delegates included those from University of Liverpool, University of Birmingham, University of Wolverhampton, Lucideon, Sanofi and many more institutions including strong support from Keele University. The hope now is to grow this event annually and to promote, not only the work carried out in the Keele Nanopharmaceutics group, but also the research strengths, which align to this from across the Faculty of Medicine and Health Sciences at Keele University. The organisation of next years’ event has already begun.
If you would like more information about speaker opportunities or attendance at next year’ s symposium please contact Dr Clare Hoskins( c. hoskins @ keele. ac. uk).
TRANSLATE 7